Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2021

Open Access 01-12-2021 | Urothelial Cancer | Correction

Correction to: Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway

Authors: Gangjun Yuan, Xin Chen, Zhuowei Liu, Wensu Wei, Qinghai Shu, Hussein Abou-Hamdan, Lijuan Jiang, Xiangdong Li, Rixin Chen, Laurent Désaubry, Fangjian Zhou, Dan Xie

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Login to get access

Excerpt

Correction to: J Exp Clin Cancer Res 37, 21 (2018)
Literature
1.
go back to reference Yuan G, Chen X, Liu Z, et al. Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway. J Exp Clin Cancer Res. 2018;37:21 https://doi.org/10.1186/s13046-018-0695-5. Yuan G, Chen X, Liu Z, et al. Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway. J Exp Clin Cancer Res. 2018;37:21 https://​doi.​org/​10.​1186/​s13046-018-0695-5.​
Metadata
Title
Correction to: Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway
Authors
Gangjun Yuan
Xin Chen
Zhuowei Liu
Wensu Wei
Qinghai Shu
Hussein Abou-Hamdan
Lijuan Jiang
Xiangdong Li
Rixin Chen
Laurent Désaubry
Fangjian Zhou
Dan Xie
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-021-01923-9

Other articles of this Issue 1/2021

Journal of Experimental & Clinical Cancer Research 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine